Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 28;17(1):15.
doi: 10.1186/s40246-023-00461-z.

Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences

Yitian Zhou  1 , Lenka Nevosadová  2 , Erik Eliasson  3   4 , Volker M Lauschke  2   5   6
Affiliations

Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences

Yitian Zhou et al. Hum Genomics. .

Abstract

Background: Genetic variability in the cytochrome P450 CYP2C9 constitutes an important predictor for efficacy and safety of various commonly prescribed drugs, including coumarin anticoagulants, phenytoin and multiple non-steroidal anti-inflammatory drugs (NSAIDs). A global map of CYP2C9 variability and its inferred functional consequences has been lacking.

Results: Frequencies of eight functionally relevant CYP2C9 alleles (*2, *3, *5, *6, *8, *11, *13 and *14) were analyzed. In total, 108 original articles were identified that included genotype data from a total of 81,662 unrelated individuals across 70 countries and 40 unique ethnic groups. The results revealed that CYP2C9*2 was most abundant in Europe and the Middle East, whereas CYP2C9*3 was the main reason for reduced CYP2C9 activity across South Asia. Our data show extensive variation within superpopulations with up to tenfold differences between geographically adjacent populations in Malaysia, Thailand and Vietnam. Translation of genetic CYP2C9 variability into functional consequences indicates that up to 40% of patients in Southern Europe and the Middle East might benefit from warfarin and phenytoin dose reductions, while 3% of patients in Southern Europe and Israel are recommended to reduce starting doses of NSAIDs.

Conclusions: This study provides a comprehensive map of the genetic and functional variability of CYP2C9 with high ethnogeographic resolution. The presented data can serve as a useful resource for CYP2C9 allele and phenotype frequencies and might guide the optimization of genotyping strategies, particularly for indigenous and founder populations with distinct genetic profiles.

Keywords: Allele frequency; Metabolizer phenotype; Pharmacogenomics; Precision medicine; Precision public health.

PubMed Disclaimer

Conflict of interest statement

YZ and VML are co-founders and shareholders of PersoMedix AB. In addition, VML is CEO and shareholder of HepaPredict AB. EE is vice-chair of the Genomic Medicine Sweden Pharmacogenomics work package, supported by grants from The Swedish Innovation Agency. EE also received funding from the Stockholm Region (CIMED). The other authors do not disclose competing interests.

Figures

Fig. 1
Fig. 1
Global distribution of CYP2C9*2 and *3 alleles. Frequencies of 65 countries were color-coded with the highest frequency in red, the average frequency across all countries in yellow, and the lowest frequency in green. Countries with no frequency information available are colored white
Fig. 2
Fig. 2
CYP2C9 metabolizer phenotype across different countries and regions. Pie charts illustrate the percentage of normal metabolizer (NM, in green), intermediate metabolizer (IM, in orange) and poor metabolizer (NM, in red) for representative countries
See this image and copyright information in PMC

References

    1. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–19. doi: 10.1136/bmj.329.7456.15. - DOI - PMC - PubMed
    1. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol. 2001;52(1):77–83. doi: 10.1046/j.0306-5251.2001.01407.x. - DOI - PMC - PubMed
    1. Insani WN, Whittlesea C, Alwafi H, Man KKC, Chapman S, Wei L. Prevalence of adverse drug reactions in the primary care setting: a systematic review and meta-analysis. PLoS ONE. 2021;16(5):e0252161. doi: 10.1371/journal.pone.0252161. - DOI - PMC - PubMed
    1. Lauschke VM, Ingelman-Sundberg M. Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing. Eur J Pharm Sci. 2019;130:65–77. doi: 10.1016/j.ejps.2019.01.024. - DOI - PubMed
    1. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–141. doi: 10.1016/j.pharmthera.2012.12.007. - DOI - PubMed

Publication types